Medical Device Firm Crypto Agility with Fused Trust Anchors
A medical device manufacturer has 1.8 million implantable cardiac monitors in the field, each with a 12-year service life. Firmware is signed with RSA-2048 and verified by a bootloader whose public key hash is fused into one-time-programmable memory at manufacture; field replacement of that trust anchor is not possible. The code-signing HSM is nine years old, the vendor ends support in 18 months, and only 40% of devices support a dual-signature boot path. The telemetry gateway uses TLS 1.2 with ECDHE-RSA and AES-128-GCM, and session data includes device diagnostics that regulators require to be retained for 10 years. A national cyber agency has advised that RSA-2048 and ECDHE-RSA will be deprecated for long-lived data before 2035. Clinical operations insists that no firmware update may require a patient visit or interrupt monitoring for more than five minutes.
1. Rank the three cryptographic risks - fused bootloader trust anchor, code-signing HSM end-of-support, and telemetry TLS - and justify the sequence.
Read the worked answer
Rank by blast radius, reversibility, and deadline. The HSM end-of-support is the nearest operational risk: in 18 months the company may lose vendor patches and validated key protection for the signing key, which threatens all firmware updates. The fused bootloader trust anchor is the most irreversible: 1.8 million devices cannot have it replaced, and 60% lack a dual-signature path. Telemetry TLS is a confidentiality risk, but it is centralized at gateways and can be upgraded with hybrid key exchange. Recommended sequence: (1) migrate code-signing keys to a supported HSM and establish dual-signing capability; (2) deploy hybrid TLS at telemetry gateways; (3) introduce post-quantum verification for new devices and the 40% dual-path fleet, while planning replacement or risk acceptance for the rest. The order reflects deadline, reversibility, and patient-safety impact, not just algorithm strength.
2. Recommend a code-signing migration plan that preserves update capability for devices already in the field. Include algorithm choices and key-ceremony controls.
Read the worked answer
Use a hybrid, overlap strategy. For devices with the dual-signature boot path, sign firmware with both the existing RSA-2048 key and an ML-DSA key so old and new trust anchors verify. New devices should trust both algorithms from manufacture. For the 60% that cannot accept a new trust anchor, do not pretend a field update can fix the bootloader; keep the existing RSA key protected in a supported HSM, restrict its use to legacy firmware, and plan device replacement or formal risk acceptance. The key ceremony should use split knowledge and dual control, a new HSM at FIPS 140-3 Level 3, audited backup and restore, and a documented rollback plan. Do not retire RSA verification until no supported device depends on it. Timestamping and rollback protection should be included in the signing policy.
3. The HSM vendor discloses a vulnerability that could allow an attacker with local access to export keys. What immediate actions and long-term changes should the manufacturer take?
Read the worked answer
Treat the signing key as potentially compromised. Activate the crypto incident plan, suspend firmware signing, isolate the HSM, preserve logs, and determine whether export was possible. Notify regulators and customers according to medical-device and breach rules. Switch to the backup key and dual-sign where devices can verify it; for legacy devices that cannot trust a new key, publish mitigation guidance and accelerate replacement because an attacker could sign malicious firmware. Revoke the old key where a revocation mechanism exists, but do not assume code-signing revocation works like TLS. Long term, require independent certification, network isolation, tamper evidence, dual control, and a tested key-compromise playbook.